ATE378064T1 - Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände - Google Patents

Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände

Info

Publication number
ATE378064T1
ATE378064T1 AT01927646T AT01927646T ATE378064T1 AT E378064 T1 ATE378064 T1 AT E378064T1 AT 01927646 T AT01927646 T AT 01927646T AT 01927646 T AT01927646 T AT 01927646T AT E378064 T1 ATE378064 T1 AT E378064T1
Authority
AT
Austria
Prior art keywords
allergic
ischemic conditions
diseases associated
treating diseases
acute inflammation
Prior art date
Application number
AT01927646T
Other languages
English (en)
Inventor
Soren Nielsen
Jorgen Frokiaer
Thomas Jonassen
Thorbjorn Bjerke
Original Assignee
Action Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Action Pharma As filed Critical Action Pharma As
Application granted granted Critical
Publication of ATE378064T1 publication Critical patent/ATE378064T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
AT01927646T 2000-05-02 2001-05-02 Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände ATE378064T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20126400P 2000-05-02 2000-05-02
DKPA200001204 2000-08-11
DKPA200001757 2000-11-22
DKPA200100369 2001-03-06

Publications (1)

Publication Number Publication Date
ATE378064T1 true ATE378064T1 (de) 2007-11-15

Family

ID=27439821

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01927646T ATE378064T1 (de) 2000-05-02 2001-05-02 Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände
AT01927645T ATE366116T1 (de) 2000-05-02 2001-05-02 Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01927645T ATE366116T1 (de) 2000-05-02 2001-05-02 Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten

Country Status (8)

Country Link
EP (2) EP1286691B1 (de)
JP (1) JP2003531863A (de)
AT (2) ATE378064T1 (de)
AU (4) AU5462501A (de)
CA (2) CA2407797A1 (de)
DE (2) DE60131393D1 (de)
NZ (1) NZ522851A (de)
WO (2) WO2001082953A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7335490B2 (en) 2002-01-09 2008-02-26 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
JP2006241043A (ja) * 2005-03-02 2006-09-14 Kirin Brewery Co Ltd 炎症性肺疾患の予防及び治療薬
ES2407107T3 (es) * 2005-08-26 2013-06-11 Abbvie Inc. Análogos de alfa-MSH terapéuticamente activos
KR20070062426A (ko) * 2005-12-12 2007-06-15 경북대학교 산학협력단 Epo 단백질을 함유하는 섬유증의 예방 또는 치료용약학적 조성물
JP2010504359A (ja) 2006-09-20 2010-02-12 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 局部麻酔および/または疼痛緩和のための、揮発性麻酔剤を送達するための方法
JP5162751B2 (ja) * 2007-01-17 2013-03-13 国立大学法人 宮崎大学 急性腎不全の検出方法
WO2009033812A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent
US20100286029A1 (en) * 2007-09-11 2010-11-11 Dorian Bevec Use of a peptide as a therapeutic agent
WO2009046833A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2712731C (en) 2008-01-22 2016-05-03 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
CN111150837B (zh) * 2020-02-11 2022-07-12 中国人民解放军陆军军医大学 Epo在抗金黄色葡萄球菌感染药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000833A2 (en) * 1986-08-08 1988-02-11 Board Of Regents, The University Of Texas System Antipyretic and anti-inflammatory peptides
EP0784480B1 (de) * 1994-11-03 2003-10-15 Boehringer Mannheim Gmbh Verwendung des erythropoietins zur behandlung von rheumatoider arthritis
TW586933B (en) * 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein

Also Published As

Publication number Publication date
WO2001082953A2 (en) 2001-11-08
DE60129221D1 (de) 2007-08-16
EP1286690B1 (de) 2007-07-04
AU2001254625B2 (en) 2006-02-02
AU2001254626B2 (en) 2006-09-21
AU5462501A (en) 2001-11-12
NZ522851A (en) 2004-11-26
EP1286691B1 (de) 2007-11-14
ATE366116T1 (de) 2007-07-15
CA2407797A1 (en) 2001-11-08
WO2001082952A2 (en) 2001-11-08
WO2001082953A3 (en) 2002-08-01
AU5462601A (en) 2001-11-12
WO2001082952A3 (en) 2002-04-18
DE60131393D1 (de) 2007-12-27
WO2001082953A8 (en) 2004-04-29
CA2407785A1 (en) 2001-11-08
EP1286691A2 (de) 2003-03-05
JP2003531863A (ja) 2003-10-28
EP1286690A2 (de) 2003-03-05

Similar Documents

Publication Publication Date Title
DE60131393D1 (de) Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände
UY26249A1 (es) Moléculas pequenas útiles en el tratamiento de las enfermedades inflamatorias ley 17164 art. 127
ATE255896T1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
ATE478669T1 (de) Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen
NO20005887L (no) Forbindelser med IgE-påvirkende egenskaper
DE69622894D1 (de) Substituierte Sulfonylphenylheterocyclen als Cyclooxygenase-2 und 5- Lipoxygenase Inhibitoren
DE60119534D1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
ATE451930T1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
CY1110405T1 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
DE69831566D1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
BR9908206A (pt) Composto, composição farmacêutica e método de tratamento de disfunçoes e doenças em mamìferos
BR0316203A (pt) Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
ATE307592T1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
DE69620306D1 (de) 4-(.Alpha.-hydroxy-.alpha.-aryl-alkylcarbonylamino)-Piperidine zur Behandlung und Prophylaxe von Erkrankungen der Harnwege
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
ATE138567T1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
DE50110552D1 (de) Verfahren zur behandlung von instabiler angina pectoris
DE602006015373D1 (de) Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten
MY130725A (en) Composition and method for treating allergic diseases
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
ATE283693T1 (de) Verwendung von pregabalin zur asthma behandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties